Increase in gut permeability and oxidized ldl is associated with post-acute sequelae of SARS-CoV-2

Post-acute sequelae of SARS-CoV-2 (PASC) is marked by persistent or newly developing symptoms beyond 4 weeks of infection. Investigating gut integrity, oxidized lipids and inflammatory markers is important for understanding PASC pathogenesis. A cross-sectional study including COVID+ with PASC, COVID...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-05, Vol.14, p.1182544-1182544
Main Authors: Mouchati, Christian, Durieux, Jared C, Zisis, Sokratis N, Labbato, Danielle, Rodgers, Michael A, Ailstock, Kate, Reinert, Brian L, Funderburg, Nicholas T, McComsey, Grace A
Format: Article
Language:English
Subjects:
C-Reactive Protein - metabolism
COVID-19
Cross-Sectional Studies
Disease Progression
gut permeability
Humans
Immunology
inflammation
Lipoproteins, LDL - metabolism
oxidized LDL (Ox-LDL)
PASC
SARS-CoV-2 - metabolism
zonulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Post-acute sequelae of SARS-CoV-2 (PASC) is marked by persistent or newly developing symptoms beyond 4 weeks of infection. Investigating gut integrity, oxidized lipids and inflammatory markers is important for understanding PASC pathogenesis. A cross-sectional study including COVID+ with PASC, COVID+ without PASC, and COVID-negative (COVID-) participants. We measured plasma markers by enzyme-linked immunosorbent assay to assess intestinal permeability (ZONULIN), microbial translocation (lipopolysaccharide-binding protein or LBP), systemic inflammation (high-sensitivity C-reactive protein or hs-CRP), and oxidized low-density lipoprotein (Ox-LDL). 415 participants were enrolled in this study; 37.83% (n=157) had prior COVID diagnosis and among COVID+, 54% (n=85) had PASC. The median zonulin among COVID- was 3.37 (IQR: 2.13, 4.91) mg/mL, 3.43 (IQR: 1.65, 5.25) mg/mL among COVID+ no PASC, and highest [4.76 (IQR: 3.2, 7.35) mg/mL] among COVID+ PASC+ (p
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1182544